United States Patent 10,669,544: Scope, Claim Construction, Patent Landscape, and Generic-Entry Risk

US Patent 10,669,544 protects a chemically modified small-interfering RNA, or siRNA, architecture. Independent claim 1 requires a duplex RNA agent with five central limitations:

A sense strand and an antisense strand.
One or more asymmetric 2′-O-alkyl modifications on the sense strand.
Two to 20 phosphorothioate modifications on the antisense strand.
Fewer asymmetric 2′-O-alkyl modifications on the antisense strand than on the sense strand.
A conjugate group on the sense strand, with the antisense strand targeting a human gene sequence. (U.S. Patent No. 10,669,544, 2020)

The patent is a platform patent. Its practical relevance is greatest for chemically stabilized, conjugated siRNA products in which the sense strand carries the delivery conjugate and the antisense strand contains terminal phosphorothioate linkages.

What technology does US Patent 10,669,544 protect?

The patent protects a strand-asymmetric siRNA design rather than a particular therapeutic target, sequence, disease, or named drug.

The claimed architecture combines:

2′-O-alkyl chemistry, including 2′-O-methyl chemistry, on the sense strand;
fewer such modifications on the antisense strand;
two to 20 antisense phosphorothioate modifications;
a conjugate group attached to the sense strand;
a duplex capable of targeting a human gene.

This structure is directed to balancing three product objectives:

Product objective	Claimed structural element
Chemical stability	2′-O-alkyl and phosphorothioate modifications
Strand-function control	More asymmetric 2′-O-alkyl modifications on the sense strand
Tissue or cellular delivery	Conjugate group on the sense strand
RNA interference	Antisense sequence complementary to a human gene
Duplex processing	Approximately 19-21 nucleotide duplex with optional 3′ overhangs

The claims do not require a particular conjugate, such as N-acetylgalactosamine, cholesterol, phospholipid, peptide, antibody, or vitamin. That omission gives claim 1 potentially broad coverage across multiple delivery technologies, subject to the requirement that the conjugate be part of the sense sequence.

How broad is independent claim 1?

Claim 1 is broad in sequence and target scope but narrow in chemical architecture.

It does not require:

a named gene;
a particular nucleotide sequence;
a particular disease indication;
a specific 2′-O-alkyl count;
a particular conjugate identity;
a defined cellular delivery pathway;
a specific overhang structure;
a specific therapeutic dose or formulation.

It does require every limitation in combination. A competing siRNA would generally need to satisfy all of the following to fall within the literal scope:

Limitation	Required by claim 1?	Commercial significance
Sense and antisense sequences	Yes	Excludes single-stranded oligonucleotides
Sense-strand 2′-O-alkyl modification	Yes	Limits coverage to modified siRNA designs
Antisense 2′-O-alkyl count lower than sense count	Yes	Creates a strand-asymmetry requirement
Antisense phosphorothioates	Yes, 2-20	Captures stabilized antisense designs
Sense-strand conjugate	Yes	Important limitation for conjugated siRNA products
Human-gene targeting	Yes	Limits the claim to human therapeutic or research targets
Particular target gene	No	Broadens potential product coverage
Particular conjugate	No	Broadens delivery-platform coverage

The most important limitation is the comparative requirement that the antisense strand have fewer asymmetric 2′-O-alkyl modifications than the sense strand. A product with equal numbers on both strands may avoid literal infringement of claim 1, although the validity and infringement analysis would depend on the claim construction and prosecution history.

What do claims 2 through 12 add?

Claims 2 through 12 define narrower siRNA implementations.

Claim	Added limitation	Effect on scope
2	At least one 2′-OMe modification	Limits 2′-O-alkyl chemistry to include 2′-O-methyl
3	Four to 12 sense-strand 2′-O-alkyl modifications	Creates a defined modification range
4	At least four modifications within six terminal nucleotides	Focuses on terminal stabilization
5	Terminal modifications plus at least one elsewhere on the sense strand	Requires distributed modification
6	At least four modifications within four terminal nucleotides	Narrower terminal pattern
7	At least two antisense phosphorothioates within the two terminal nucleotides	Requires terminal antisense stabilization
8	Two terminal phosphorothioates also on the sense strand	Creates bilateral terminal stabilization
9	At least three antisense phosphorothioates	Narrows claim 1's two-to-20 range
10	Fully complementary sense and antisense strands	Excludes internal mismatches
11	At least 21 nucleotides; approximately 19-nucleotide duplex	Covers canonical siRNA dimensions
12	19-21 nucleotide duplex with one or two two-nucleotide 3′ overhangs	Covers common Dicer-like duplex architecture

Claims 3 through 8 are particularly relevant to product-by-product infringement analysis because they require modification placement, not merely the presence of a modification. A competitor could use the same general chemistry while avoiding a dependent claim by moving modifications away from the terminal positions.

What additional chemistry is protected by claims 13 through 20?

Claims 13 through 20 extend the platform beyond 2′-O-alkyl and phosphorothioate chemistry.

The listed modifications include:

2′-5′ linkages;
L-ribose;
L-arabinose;
locked nucleic acids;
hexose nucleic acids;
cyclohexane nucleic acids;
nucleobase modifications;
cationic groups;
zwitterionic groups;
conjugate groups.

Claims 13 through 16 apply these additional modifications to the sense sequence. Claims 17 through 20 apply them to the antisense sequence.

The claims are not limited to one specific chemical implementation. They therefore create a layered coverage structure:

Claim 1 captures the core asymmetric siRNA architecture.
Claims 2 through 12 capture preferred 2′-O-alkyl, phosphorothioate, terminal, and duplex configurations.
Claims 13 through 20 add alternative chemical modifications to either strand.

The broader chemical lists may face greater validity and construction scrutiny than the narrower structural claims. Terms such as “asymmetric modification,” “conjugate group,” and “modified sugar” would be evaluated in light of the specification, prosecution history, and applicable claim-construction principles.

What siRNA products could potentially fall within the claims?

A product is most exposed when it has all of the following characteristics:

a duplex siRNA;
a sense-strand delivery conjugate;
more sense-strand 2′-O-alkyl modifications than antisense-strand 2′-O-alkyl modifications;
at least two antisense phosphorothioate linkages;
a human gene target;
a conventional 19-21 nucleotide duplex.

The patent may be relevant to conjugated siRNA products directed to hepatic, ocular, central nervous system, or other tissues if the chemistry and strand orientation satisfy the claims.

The patent does not automatically cover every siRNA product. Potential design-around routes include:

placing the conjugate on the antisense strand;
using an equal number of 2′-O-alkyl modifications on both strands;
eliminating or reducing antisense phosphorothioate modifications below the claimed range;
using a single-stranded RNA agent;
using a non-RNA modality;
altering the duplex architecture;
using chemistry outside the listed modification categories.

Each route requires analysis of dependent claims and potential equivalents.

How strong is the patent estate?

The claims have meaningful commercial breadth because claim 1 is target-agnostic and does not identify a specific conjugate. The main strength is the combination of chemical and architectural limitations in one independent claim.

Strengths

Coverage is not limited to one human gene.
Coverage is not limited to one disease.
The sense-strand conjugate requirement aligns with common conjugated-siRNA designs.
The claim covers ranges rather than a single exact modification pattern.
Claims 13 through 20 extend coverage to multiple sugar, linkage, and charge modifications.
The dependent claims provide fallback positions for terminal modification patterns and canonical siRNA dimensions.

Weaknesses

Claim 1 requires several limitations simultaneously.
The comparative “fewer” limitation creates a clear design-around axis.
“Asymmetrical” and related chemical terms may require detailed construction.
The patent does not, from the claims supplied, establish protection for a particular marketed drug.
Earlier siRNA modification patents may create prior-art and double-patenting issues.
A competitor may avoid literal infringement through strand orientation, modification counts, or conjugate placement.

The most defensible claims in litigation would likely be the narrower claims directed to defined modification counts and terminal placement, assuming adequate written description and enablement support in the specification.

What is the Orange Book status of US Patent 10,669,544?

US Patent 10,669,544 is not an Orange Book-listed patent merely because it covers a pharmaceutical technology. The FDA Orange Book generally lists patents submitted by an NDA holder for an approved drug, including patents claiming the drug substance, drug product, or approved method of use. A platform patent covering a class of siRNA architectures may not appear in the Orange Book unless it has been properly submitted in connection with an approved NDA. (FDA, 2024)

The claims supplied do not identify:

an approved active ingredient;
an NDA;
a drug product;
a dosage form;
a method of use for an approved indication;
an Orange Book listing.

Consequently, Paragraph IV exposure cannot be assessed from the patent claims alone. If the patent is not listed against an approved NDA, it ordinarily would not create a conventional Orange Book Paragraph IV filing pathway. Enforcement could still proceed under ordinary patent litigation theories if a commercial product practices the claims.

When does US Patent 10,669,544 lose exclusivity?

The exact expiration date depends on the patent family’s earliest effective nonprovisional or international filing date, terminal disclaimers, patent-term adjustment, and any patent-term extension. The issue date, June 2, 2020, is not the relevant starting point for the ordinary 20-year patent term. (U.S. Patent No. 10,669,544, 2020; USPTO, 2024)

For a patent claiming priority to an earlier PCT or U.S. filing, the ordinary term is generally measured from the earliest effective nonprovisional filing date, subject to statutory adjustments. A complete exclusivity calculation must therefore use the USPTO continuity and maintenance records, not the claims alone.

The practical exclusivity analysis should separate:

Exclusivity category	Relevance
Patent term	Depends on priority chain and PTA
FDA new-drug exclusivity	Applies to an approved drug, not automatically to this platform patent
Orphan-drug exclusivity	Depends on an orphan designation and approval
Pediatric exclusivity	Adds six months to qualifying regulatory exclusivity
Data exclusivity	Depends on the approved product and regulatory pathway
Orange Book listing	Depends on NDA submission and FDA acceptance

Which companies could be affected?

The patent is most relevant to companies developing chemically modified, conjugated siRNA products. The competitive group includes:

Alnylam Pharmaceuticals;
Arrowhead Pharmaceuticals;
Ionis Pharmaceuticals and affiliated development partners;
Silence Therapeutics;
Dicerna, now part of Novo Nordisk;
Roche and other companies pursuing RNA interference partnerships;
generic or follow-on manufacturers attempting to reproduce approved siRNA products.

Exposure cannot be inferred from company participation in RNA therapeutics alone. It requires sequence-level and chemistry-level comparison against claims 1 through 20.

A company using a different delivery conjugate may remain exposed because claim 1 does not specify the conjugate identity. A company using the same target sequence may avoid the patent if its strand chemistry does not satisfy the asymmetrical modification and antisense phosphorothioate requirements.

What patent litigation and Paragraph IV risks exist?

The claims create two distinct litigation scenarios.

Platform-patent litigation

A patent owner could assert the patent against:

manufacture of a covered siRNA;
importation of a covered siRNA;
sale of a covered research or commercial product;
supply of a covered active ingredient;
development of a product that practices the claimed architecture.

The likely disputed issues would include claim construction, written description, enablement, anticipation, obviousness, prosecution disclaimer, and the scope of “conjugate group” and “asymmetric modification.”

Generic or follow-on litigation

For an approved siRNA product, a follow-on applicant could face:

an Orange Book Paragraph IV certification if the patent is listed;
a 30-month litigation stay under the Hatch-Waxman framework if statutory conditions are met;
a patent-infringement action;
a non-infringement or invalidity defense;
a later launch subject to patent settlement terms.

A patent covering a formulation or platform chemistry does not necessarily block approval of a follow-on product. The commercial effect depends on whether the follow-on product practices the asserted claims.

No settlement terms, licensing agreement, or litigation outcome can be established from the claims supplied. Patent ownership and current enforceability must be confirmed against USPTO assignment, maintenance, continuity, and court records.

What manufacturing and intellectual-property barriers does the patent create?

The patent may increase manufacturing risk where a product requires:

strand-specific placement of 2′-O-methyl or other 2′-O-alkyl monomers;
controlled terminal phosphorothioate patterns;
conjugation at a defined position on the sense strand;
duplex assembly with a defined overhang;
quality-control assays capable of distinguishing positional isomers.

The manufacturing barrier is not necessarily the chemical synthesis itself. It is the need to reproduce the exact modification map and conjugation configuration consistently at commercial scale.

For freedom-to-operate work, a manufacturer should compare:

the full sense-strand sequence;
the full antisense-strand sequence;
each 2′-O-alkyl position;
each phosphorothioate position;
the conjugate identity and attachment site;
duplex length and overhang structure;
additional sugar, linkage, nucleobase, charge, or zwitterionic modifications.

Analytical characterization should be capable of establishing positional modification patterns, not merely bulk chemical composition.

How does this patent compare with typical siRNA patent coverage?

Coverage category	US 10,669,544	Typical competing patent category
Target sequence	Broad, human-gene based	Often sequence-specific
Chemical modification	Broad but architecture-dependent	May focus on a defined chemistry
Conjugate	Required on sense strand but not specified	Often claims a specific ligand
Formulation	Not apparent from supplied claims	May claim nanoparticles, buffers, or dosage forms
Method of use	Not target-disease specific	Often claims treatment of a named disease
Manufacturing	Indirectly implicated	May separately claim synthesis or conjugation
Duplex design	Explicitly addressed	Varies by patent family
Regulatory linkage	Not established	May be listed against a marketed NDA

The patent is strongest as a chemistry-and-architecture layer. It is not, based on the supplied claims, a complete product estate. A commercially important siRNA would typically require separate protection for the sequence, conjugate, formulation, method of use, manufacturing process, and possibly crystalline or particulate form.

Key Takeaways

US Patent 10,669,544 claims a conjugated, chemically modified siRNA architecture.
Claim 1 requires more asymmetric 2′-O-alkyl modifications on the sense strand than on the antisense strand.
The antisense strand must contain two to 20 phosphorothioate modifications.
The conjugate must be part of the sense sequence.
Claims 3 through 8 create narrower protection for modification counts and terminal placement.
Claims 10 through 12 cover fully complementary and canonical siRNA duplex structures.
Claims 13 through 20 extend protection to alternative sugars, linkages, nucleobases, charge groups, and conjugates.
The patent is not automatically an Orange Book patent.
Paragraph IV risk depends on whether the patent is listed against an approved NDA and whether a follow-on product practices the claims.
The exact expiration date requires the complete continuity, priority, PTA, terminal-disclaimer, and maintenance history.
The principal design-around options involve conjugate placement, relative modification counts, phosphorothioate count, and duplex architecture.

FAQs

Does US Patent 10,669,544 cover GalNAc-siRNA products?

It may cover a GalNAc-siRNA product if the GalNAc conjugate is attached to the sense strand and the product satisfies the required asymmetric 2′-O-alkyl and antisense phosphorothioate limitations. The claim does not expressly require GalNAc.

Can an siRNA avoid the patent by moving the conjugate to the antisense strand?

Moving the conjugate to the antisense strand may avoid literal infringement of claim 1 because claim 1 requires the sense sequence to comprise a conjugate group. The dependent claims must also be reviewed, together with potential equivalents arguments.

Does the patent cover single-stranded antisense oligonucleotides?

No. The claims require a sense sequence and an antisense sequence forming an RNA agent. A single-stranded antisense oligonucleotide does not satisfy that structural requirement.

Does a two-nucleotide 3′ overhang create infringement by itself?

No. The overhang is only one limitation in claims 11 and 12. Infringement requires satisfaction of all limitations of the asserted claim.

Is the patent a complete blocking right for an approved siRNA drug?

No. It is one potential patent layer. A commercial siRNA product may also be subject to sequence, conjugate, formulation, method-of-use, manufacturing, regulatory-exclusivity, and other patent rights.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

U.S. Patent No. 10,669,544. (2020). RNA agent for inhibiting expression of a target human gene. United States Patent and Trademark Office.

United States Patent and Trademark Office. (2024). Patent term adjustment. USPTO.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	479752	⤷ Start Trial
Australia	2004220556	⤷ Start Trial
Australia	2004227414	⤷ Start Trial
Australia	2004229519	⤷ Start Trial
Australia	2004232964	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,669,544

Summary for Patent: 10,669,544